



NDA 21153/S-049  
NDA 21957/S-016  
NDA 22101/S-013

## SUPPLEMENT APPROVAL

AstraZeneca LP  
Attention: Judy W Firor  
Director, Global Regulatory Affairs and Patient Safety  
1800 Concord Pike PO Box 8355  
Wilmington, DE 19803-8355

Dear Ms. Firor:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received November 8, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nexium (esomeprazole magnesium) Delayed-Release Capsules, 20 mg and 40 mg and Nexium (esomeprazole magnesium) Delayed-Release Oral Suspension, 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg.

We acknowledge receipt of your amendments dated January 24, 2014, February 4, 2014 and February 17, 2014.

We also refer to our letter dated October 10, 2013, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Nexium. This information pertains to the risk of fetal harm in pregnancy, with the use of esomeprazole.

These supplemental new drug applications provides for revisions to the labeling for Nexium. The agreed upon changes to the language included in our October 10, 2013, letter are noted in the attached label. The following sections were impacted by the labeling revisions in the package insert:

### HIGHLIGHTS OF PRESCRIBING INFORMATION

- USE IN SPECIFIC POPULATIONS

#### FULL PRESCRIBING INFORMATION: CONTENTS

#### FULL PRESCRIBING INFORMATION

#### 8. USE IN SPECIFIC POPULATION

- 8.1 Pregnancy
- 8.4 Pediatric use

#### 13. NONCLINICAL TOXICOLOGY

- 13.2 Animal Toxicology and/or Pharmacology

## **APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21153/S-049  
NDA 21957/S-016  
NDA 22101/S-013  
Page 3

If you have any questions, call CDR Stacy Barley, Senior Regulatory Project Manager, at (301) 796-2137.

Sincerely,

*{See appended electronic signature page}*

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology and Inborn Errors  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOYCE A KORVICK  
02/25/2014